Oxycodone/naloxone
This is an old revision of this page, as edited by Anypodetos (talk | contribs) at 08:18, 30 August 2016 (→Adverse effects: IV naloxone has the same receptor affinity as oral one...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Combination of | |
---|---|
Oxycodone | Opioid analgesic |
Naloxone | Opioid receptor antagonist |
Clinical data | |
AHFS/Drugs.com | International Drug Names UK Drug Information |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
(verify) |
Oxycodone/naloxone is a combination analgesic drug available as modified-release tablets under the trade names Targin (produced by Mundipharma), Targiniq and Targinact.
The oxycodone component is an opioid and is responsible for the pain-relieving effects. Naloxone opposes the effects of opioids but is poorly absorbed into the body when given orally, meaning almost all the dose stays within the gastrointestinal tract and reduces the local side effects from the oxycodone. Constipation was significantly relieved in a 2008 study.[1] The drug was released in 2006 in Germany and is available in some other European countries since 2009.[2]
Adverse effects
If the drug is used off license by crushing the tablet and dissolving it for injection, it may precipitate severe opiate withdrawal symptoms due to the much higher bioavailability of intravenous naloxone compared to oral naloxone. In simpler terms, since naloxone is an opioid antagonist, it will bind to the opioid receptors in the brain and block the analgesic effect of the oxycodone.
See also
- Hydrocodone/paracetamol
- Hydrocodone/ibuprofen
- Oxycodone/paracetamol
- Oxycodone/aspirin
- Morphine/naltrexone
- Fentanyl/fluanisone
References
- ^ Simpson K, et al. (December 2008). "Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain". Curr Med Res Opin. 24 (12): 3503–3512. doi:10.1185/03007990802584454. PMID 19032132. Retrieved 2009-04-09.
- ^ Mundipharma (2009-01-26). "Targin (oral oxycodone/naloxone prolonged-release tablet) now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation". Retrieved 2009-04-09.
Stool softeners | |
---|---|
Stimulant laxatives | |
Bulk-forming laxatives | |
Lubricant laxatives | |
Osmotic laxatives | |
Enemas | |
Opioid antagonists | |
Others |
Nervous system |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Circulatory system |
| ||||||||||||||
Other |
| ||||||||||||||
Emetic | |||||||||||||||
|
μ-opioid (MOR) |
| ||||
---|---|---|---|---|---|
δ-opioid (DOR) |
| ||||
κ-opioid (KOR) |
| ||||
Nociceptin (NOP) |
| ||||
Others |
|
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs that are a combination of chemicals
- All stub articles